Evofem Biosc. - Chancen und Risiken

Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora

https://www.ariva.de/news/...ounces-last-patient-enrolled-for-7535054

Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019

https://evofem.investorroom.com/...ide-Corporate-Update-on-May-7-2019

Balance at December 31, 2018                                                                 25,867,248 Shares

As of March 31, 2019, warrants to purchase approximately 3,587,853 shares of the Company's common stock remain outstanding at a weighted average exercise price of $4.68 per share.

The number of shares of the registrant?s common stock, $0.0001 par value, outstanding as of April 30, 2019 was 35,367,191.

https://www.sec.gov/Archives/edgar/data/1618835/000161883519000084/evfm-331201910xq.htm

To approve the issuance of our common stock pursuant to a private placement financing, including shares of common stock issuable upon the exercise of warrants that will result in a change of control for purposes of Nasdaq Listing Rule 5635(b); and

http://app.quotemedia.com/data/...pe=DEFR14A&dateFiled=2019-05-10

http://app.quotemedia.com/data/...SC+13G%2FA&dateFiled=2019-05-10

http://app.quotemedia.com/data/...SC+13G%2FA&dateFiled=2019-05-10